Skip to content
OpenCapital
Get started

Castle Biosciences CSTL PP&E (Gross)

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S2×+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's pp&e (gross).

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's PP&E (gross)?
Castle Biosciences (CSTL) reported PP&E (gross) of $120.8M in Q1 2026.
How has Castle Biosciences's PP&E (gross) changed year-over-year?
Castle Biosciences's PP&E (gross) increased by 73.5% year-over-year, from $69.64M to $120.8M.
What is the long-term trend for Castle Biosciences's PP&E (gross)?
Over 4 years (2021 to 2025), Castle Biosciences's PP&E (gross) has grown at a 74.3% compound annual growth rate (CAGR), from $12.54M to $115.74M.
What does PP&E (gross) mean?
Total cost of all property, plant, and equipment before deducting accumulated depreciation — the gross investment in tangible assets.